Replies to post #59617 on Biotech Values

[DewDiligence]

>where do you think those #s will be at the end of 08?<

I don’t especially care as long as Copaxone maintains a decent-sized share. Even at half the existing volume, a substitutable generic Copaxone (what MNTA and Sandoz are working on) will be worth pretty big money.